Published in J Bioenerg Biomembr on June 01, 2010
Mitochondria: the next (neurode)generation. Neuron (2011) 3.06
Metabolic disturbances in diseases with neurological involvement. Aging Dis (2013) 0.84
Targeting sirtuin-1 in Huntington's disease: rationale and current status. CNS Drugs (2013) 0.79
Metabolism in HD: still a relevant mechanism? Mov Disord (2014) 0.77
ROCK-phosphorylated vimentin modifies mutant huntingtin aggregation via sequestration of IRBIT. Mol Neurodegener (2012) 0.76
The Association of VDAC with Cell Viability of PC12 Model of Huntington's Disease. Front Oncol (2016) 0.75
Modulation of Molecular Chaperones in Huntington's Disease and Other Polyglutamine Disorders. Mol Neurobiol (2016) 0.75
Thalamic metabolic abnormalities in patients with Huntington's disease measured by magnetic resonance spectroscopy. Braz J Med Biol Res (2013) 0.75
Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature (2006) 15.69
Non-cell autonomous toxicity in neurodegenerative disorders: ALS and beyond. J Cell Biol (2009) 5.65
Mitochondrial dynamics--fusion, fission, movement, and mitophagy--in neurodegenerative diseases. Hum Mol Genet (2009) 5.15
Tripartite synapses: glia, the unacknowledged partner. Trends Neurosci (1999) 5.02
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders. Nat Rev Drug Discov (2008) 4.43
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci (2002) 4.15
Tripartite synapses: astrocytes process and control synaptic information. Trends Neurosci (2009) 4.01
Glial cells as intrinsic components of non-cell-autonomous neurodegenerative disease. Nat Neurosci (2007) 3.02
Multiple roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci (2009) 2.95
Mutant huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol (2004) 2.65
Expression of mutant huntingtin in glial cells contributes to neuronal excitotoxicity. J Cell Biol (2005) 2.57
Mitochondrial fusion, fission and autophagy as a quality control axis: the bioenergetic view. Biochim Biophys Acta (2008) 2.56
Glutamate decreases mitochondrial size and movement in primary forebrain neurons. J Neurosci (2003) 2.56
Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease. Nat Rev Neurosci (2000) 2.44
Astrocyte metabolism and signaling during brain ischemia. Nat Neurosci (2007) 2.39
Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet (2004) 2.31
N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci (2008) 2.18
Mitochondria exert a negative feedback on the propagation of intracellular Ca2+ waves in rat cortical astrocytes. J Cell Biol (1999) 2.12
Mitochondria and neuronal activity. Am J Physiol Cell Physiol (2006) 2.11
Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol (1996) 2.09
Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet (2008) 1.98
The relationship between free and total calcium concentrations in the matrix of liver and brain mitochondria. J Biol Chem (2003) 1.97
Synaptic mitochondria are more susceptible to Ca2+overload than nonsynaptic mitochondria. J Biol Chem (2006) 1.93
Expression of mutant huntingtin in mouse brain astrocytes causes age-dependent neurological symptoms. Proc Natl Acad Sci U S A (2009) 1.87
Huntington's disease: the challenge for cell biologists. Trends Cell Biol (2000) 1.80
Weight loss in early stage of Huntington's disease. Neurology (2002) 1.79
Mutant huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis (2006) 1.78
Nature and cause of mitochondrial dysfunction in Huntington's disease: focusing on huntingtin and the striatum. J Neurochem (2010) 1.73
Mitochondrial trafficking and morphology in healthy and injured neurons. Prog Neurobiol (2006) 1.72
3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem (2005) 1.68
The role of abnormal mitochondrial dynamics in the pathogenesis of Alzheimer's disease. J Neurochem (2009) 1.67
Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA- and ROS-dependent pathway. Cell Death Differ (2009) 1.66
In situ respiration and bioenergetic status of mitochondria in primary cerebellar granule neuronal cultures exposed continuously to glutamate. J Biol Chem (2004) 1.57
Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol (2009) 1.43
Mitochondrial dysfunction in Huntington's disease: the bioenergetics of isolated and in situ mitochondria from transgenic mice. J Neurochem (2007) 1.32
Mitochondria and Huntington's disease pathogenesis: insight from genetic and chemical models. Ann N Y Acad Sci (2008) 1.29
Mutant huntingtin in glial cells exacerbates neurological symptoms of Huntington disease mice. J Biol Chem (2010) 1.25
Astrocytic contributions to bioenergetics of cerebral ischemia. Glia (2005) 1.22
Increased susceptibility of striatal mitochondria to calcium-induced permeability transition. J Neurosci (2003) 1.20
Enhanced Akt signaling is an early pro-survival response that reflects N-methyl-D-aspartate receptor activation in Huntington's disease knock-in striatal cells. J Biol Chem (2003) 1.20
Mitochondrial-dependent Ca2+ handling in Huntington's disease striatal cells: effect of histone deacetylase inhibitors. J Neurosci (2006) 1.19
Astrocyte mitochondrial mechanisms of ischemic brain injury and neuroprotection. Neurochem Res (2004) 1.06
Age-dependent changes in the calcium sensitivity of striatal mitochondria in mouse models of Huntington's Disease. J Neurochem (2005) 1.05
Cyclosporin A increases mitochondrial calcium uptake capacity in cortical astrocytes but not cerebellar granule neurons. J Bioenerg Biomembr (2006) 1.05
Mitochondria modulate Ca2+-dependent glutamate release from rat cortical astrocytes. J Neurosci (2008) 1.01
Cellular factors controlling neuronal vulnerability in the brain: a lesson from the striatum. Neurology (2000) 0.93
Juvenile Huntington's disease: does a dosage-effect pathogenic mechanism differ from the classical adult disease? Mech Ageing Dev (2005) 0.93
Juvenile Huntington chorea: clinical, ultrastructural, and biochemical studies. Neurology (1978) 0.93
Mitochondrial trafficking in neurons: a key variable in neurodegeneration? J Bioenerg Biomembr (2004) 0.92
Early resistance to cell death and to onset of the mitochondrial permeability transition during hepatocarcinogenesis with 2-acetylaminofluorene. Proc Natl Acad Sci U S A (2003) 0.90
Targeting glial cells to elucidate the pathogenesis of Huntington's disease. Mol Neurobiol (2010) 0.88
In situ mitochondrial Ca2+ buffering differences of intact neurons and astrocytes from cortex and striatum. J Biol Chem (2008) 0.87
Cyclosporin A protects striatal neurons in vitro and in vivo from 3-nitropropionic acid toxicity. J Comp Neurol (2000) 0.83
Toxicity of beta-amyloid in HEK293 cells expressing NR1/NR2A or NR1/NR2B N-methyl-D-aspartate receptor subunits. Neurochem Int (2007) 0.82
Techniques to investigate neuronal mitochondrial function and its pharmacological modulation. Curr Drug Targets (2011) 0.77
[Astrocytes in Huntington's chorea: accomplice or guilty of the neuronal death?]. Med Sci (Paris) (2007) 0.75